Fingerprint
Dive into the research topics of 'A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Research output: Contribution to journal › Article › peer-review
10
Scopus
citations